Provided by Tiger Fintech (Singapore) Pte. Ltd.

C4 Therapeutics, Inc.

1.38
+0.125010.00%
Volume:1.17M
Turnover:1.65M
Market Cap:97.61M
PE:-0.91
High:1.49
Open:1.23
Low:1.20
Close:1.25
Loading ...

CCCC Design & Consulting Group 2024 Profit Down 0.8%, Revenue Slips 8%

MT Newswires Live
·
28 Mar

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
03 Mar

UBS Adjusts C4 Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating

MT Newswires Live
·
03 Mar

C4 Therapeutics: Promising Clinical Developments and Strategic Plans Justify Buy Rating

TIPRANKS
·
02 Mar

C4 Therapeutics Reports Strong 2024 Financial Performance and Clinical Progress

TIPRANKS
·
28 Feb

C4 Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Feb

C4 Therapeutics Inc: Cash, Cash Equivalents and Marketable Securities of $267.3 Mln as of Dec 31, 2024; Expected to Provide Runway Into 2027

THOMSON REUTERS
·
27 Feb

C4 Therapeutics Inc Q4 Shr View $-0.48 -- Lseg Ibes Data

THOMSON REUTERS
·
27 Feb

C4 Therapeutics Inc: Qtrly Loss per Share $0.49

THOMSON REUTERS
·
27 Feb

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
26 Feb

C4 Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
24 Feb

C4 Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire
·
24 Feb

C4 Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
18 Feb

UBS Downgrades C4 Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $18

MT Newswires Live
·
14 Feb

Malaysia's ECRL: A closer look at the US$11.2b railway’s promises of boosting jobs for locals and making money

CNA
·
04 Feb

3 Penny Stocks On US Exchanges To Consider In January 2025

Simply Wall St.
·
16 Jan

BRIEF-C4 Therapeutics Data In Melanoma & Colorectal Cancer Expected In Second Half Of 2025

Reuters
·
14 Jan

C4 Therapeutics Outlines 2025 Milestones and Achievements

TIPRANKS
·
14 Jan

C4 Therapeutics: Data in Melanoma & Colorectal Cancer Expected in Second Half of 2025

THOMSON REUTERS
·
14 Jan